Dalzanemdor (INN ;[1] development code SAGE-718) is experimental drug being investigated for the treatment of neurological disorders and cognitive impairment.[2] It acts as a positive allosteric modulator of the NMDA receptor, whose activity is essential for learning, memory, and cognition.[3] Dalzanemdor is an analogue of the neurosteroid 24S-hydroxycholesterol.[3]
![]() | |
Clinical data | |
---|---|
Other names | SAGE-718 |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
KEGG | |
ChEMBL | |
Chemical and physical data | |
Formula | C26H41F3O2 |
Molar mass | 442.607 g·mol−1 |
As of 2022, dalzanemdor is in Phase II clinical trials[3] for Alzheimer's disease,[4][5][6] Parkinson's disease, and Huntington's disease.[7][8]
References
edit- ^ "Investigational SAGE-718 Granted Nonproprietary Name of Dalzanemdor". Sage Therapeutics. December 5, 2023.
- ^ Hill MD, Blanco MJ, Salituro FG, Bai Z, Beckley JT, Ackley MA, et al. (July 2022). "SAGE-718: A First-in-Class N-Methyl-d-Aspartate Receptor Positive Allosteric Modulator for the Potential Treatment of Cognitive Impairment". Journal of Medicinal Chemistry. 65 (13): 9063–9075. doi:10.1021/acs.jmedchem.2c00313. PMID 35785990. S2CID 250250073.
- ^ a b c "SAGE-718". ALZFORUM.
- ^ Shapiro L (5 April 2022). "#AAN2022 – SAGE-718 May Help With Cognitive Function in Alzheimer's". BioNews, Inc.
- ^ "SAGE-718 in Patients With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease: Results From the Phase 2 LUMINARY Study" (PDF). American Academy of Neurology (AAN) 74th Annual Meeting Abstract.
- ^ Castañeda R (16 November 2021). "Regulatory roundup: Sage Alzheimer's asset likely to progress after Phase IIa completion". Clinical Trials Arena. Archived from the original on 28 May 2022. Retrieved 13 July 2022.
- ^ "Sage Therapeutics Provides Important Update On The Clinical Development Program For Sage's Investigational Drug, SAGE-718". Huntington's Disease Society of America. 22 February 2022.
- ^ Wexler M (21 September 2021). "SAGE-718 on FDA Fast Track as Potential Huntington's Disease Therapy". BioNews, Inc.
External links
edit